Patents by Inventor Janice Bradshaw

Janice Bradshaw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 3974153
    Abstract: Cephalosporin antibiotics in which the 7.beta.-acylamido group has the structure ##EQU1## where R.sup.1 is a furyl, thienyl or phenyl group and R.sup.2 is a C.sub.1 -C.sub.4 alkyl, C.sub.3 C.sub.7 cycloalkyl or phenyl group and in which the 3-position substituent is a carbamoyloxymethyl group possess a particularly valuable combination of properties, exhibiting high antibacterial activity against a broad range of gram positive and gram negative organisms, particularly high stability to .beta.-lactamases produced by various organisms, and stability in vivo. The compounds are syn isomers or exist as mixtures of syn and anti isomers containing at least 90% of the syn isomer. Particularly important compounds of this type are (6R,7R)-3-carbamoyloxymethyl -7-[2-(fur-2-yl)-2-methoxyiminoacetamido]ceph-3-em-4-carboxylic acid (syn isomer) and its non-toxic derivatives, e.g. the sodium salt.
    Type: Grant
    Filed: August 13, 1974
    Date of Patent: August 10, 1976
    Assignee: Glaxo Laboratories Limited
    Inventors: Martin Christopher Cook, Gordon Ian Gregory, Janice Bradshaw
  • Patent number: 3971778
    Abstract: The invention provides novel antibiotic compounds which are 7.beta.-acylamidoceph-3-em-4-carboxylic acids, and non-toxic derivatives thereof characterized in that the acylamido group has the structure ##EQU1## where R is a hydrogen atom or an organic group and R.sup.a is an etherifying monovalent organic group linked to the oxygen atom through a carbon atom. The compounds are syn isomers or exist as mixtures containing at least 75% of the syn isomer. These antibiotic compounds possess high antibacterial activity against a range or gram positive and gram negative organisms coupled with particularly high stability to .beta.-lactamases produced by various gram negative organisms. The invention is also concerned with the administration of the compounds.
    Type: Grant
    Filed: November 7, 1972
    Date of Patent: July 27, 1976
    Assignee: Glaxo Laboratories Limited
    Inventors: Martin Christopher Cook, Gordon Ian Gregory, Janice Bradshaw
  • Patent number: 3966717
    Abstract: The invention provides novel antibiotic compounds comprising 7.beta.-acylamido-3-carbamoyloxymethylceph-3-em-4-carboxylic acids and non-toxic derivatives thereof wherein the acylamido group has the structure ##EQU1## IN WHICH R is a carbocyclic or heterocyclic aryl group and R.sup.a is a lower alkyl, cycloalkyl or phenyl group. The compounds are syn isomers or exist as mixtures containing at least 75% of the syn isomer. These antibiotic compounds possess high antibacterial activity against a range of gram positive and gram negative organisms coupled with particularly high stability to .beta.-lactamases produced by various organisms and stability in the presence of human serum. The invention is also concerned with the administration of the compounds.
    Type: Grant
    Filed: November 8, 1973
    Date of Patent: June 29, 1976
    Assignee: Glaxo Laboratories Limited
    Inventors: Martin Christopher Cook, Gordon Ian Gregory, Janice Bradshaw
  • Patent number: 3932385
    Abstract: The invention provides novel antibiotic compounds which are 6.beta.-acylamidopenam-3-carboxylic acids, and non-toxic derivatives thereof, characterized in that the acylamido group has the structure ##EQU1## WHERE R is a hydrogen atom or an organic group and R.sup.a is an etherifying monovalent organic group linked to the oxygen atom through a carbon atom. The compounds may be either syn or anti isomers or may exist as mixtures e.g. containing at least 75 percent of one isomer. These antibiotic compounds possess high antibacterial activity against a range of gram positive organisms including penicillinase - producing staphylococci coupled with high activity against strains of the gram-negative organism Haemophilus influenzae. The invention is also concerned with the administration of the compounds.
    Type: Grant
    Filed: November 7, 1972
    Date of Patent: January 13, 1976
    Assignee: Glaxo Laboratories Limited
    Inventors: Martin Christopher Cook, Gordon Ian Gregory, Janice Bradshaw